



Health Partners Plans

PHARMACY AND THERAPEUTICS COMMITTEE MEDICAID MEETING MINUTES February 25, 2021

Attendance: Onsite

Date: February 25, 2021

Skype Conference

Chris Casella, Director of Pharmacy; Connie Chan, Staff/Clinical Pharmacist; Claudine Clarke, MD, Practicing Physician; Jaden Daubert, Pharmacy Resident; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Manager of Pharmacy Services and Staff/Clinical Pharmacist; George E. Downs, Director of the Annual Fund, Dean Emeritus and Professor; Leah Finken, Staff/Clinical Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Jerry George, Staff/Clinical Pharmacist; Evan Halperin, Pharmacy Student Intern; Samantha Jackson, Clinical Pharmacist; Lawrence Jones, Director of Pharmacy, Phoenixville Hospital; Kaylei Koerwitz, Clinical Programs Pharmacist; Dr. Tania Koley, Medical Director; Hannah Livengood, Formulary Pharmacist; Xin Lu, Pharmacy Student Intern; Brandi Mahler, Supervisor Pharmacy Technicians; Karleen Melody; Renee Mercer, Vice President Member and Provider Relations; Dr. Lou Parrott, Community Behavior Health; Kateryna Puia, Clinical Programs Pharmacist; Gino Raineri, Staff/Clinical Pharmacist; Sara Sadiq, Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Lauren Stabler, Managed Care Pharmacy Resident; Shelley Staffa, Clinical Pharmacist; Dr. Laura Lee Swan, Pediatrician; Fallan Vaisberg, Staff/Clinical Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Robin Wheeler, Staff/Clinical Pharmacist

Excused: *Kay Chan, Manager Pharmacy Benefit Design and Audits; Oluwatoyin Fadeyibi, Community Behavior Health; Merleen Harris-Williams, Medical Director; Shatara Lewis, Analyst; Howard Lu, Vice President Chief Clinical Officer*

Minutes taken by: Joana Iverson

I. Administrative Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Minutes Review/Approval	<i>-C. Casella presented the minutes from the October 2020 meeting to the Committee for review.</i>	<i>The Committee approved the minutes from our last meeting as presented.</i>	<i>C. Casella</i>	<i>Resolved</i>
Administrative Update	<i>-C. Casella reviewed the COVID-19 crisis, Medicaid expansion, and P&P updates</i>	<i>Informational</i>	<i>C. Casella</i>	<i>Informational</i>

II. Drug Formulary Review/Update/Removal

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
Prior Authorization Criteria – Review	<p>The Committee reviewed the Prior Authorization Criteria. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Kuvan • Nuedexta • Palynziq • Xyrem/Xywav 	<p>The Committee approved the criteria as presented. It will be sent to PARP for approval.</p>	<p>S. Jackson F. Vaisberg S. Staffa</p>	<p>Resolved</p>
Supplemental Formulary Removals	<p>The Committee reviewed the Supplemental Formulary Removals. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Fluocinolone otic solution • Innospire Elegance nebulizer • Rena-Vite Rx tab • Strovite One tab • Vitrexyl tablet • High cost diabetic supplies from select manufacturers (lancets and pen needles/syringes) 	<p>The Committee approved the criteria as presented. It will be sent to PARP for approval.</p>	<p>C. Casella</p>	<p>Resolved</p>
Quantity Limit Additions	<p>The Committee reviewed the Quantity Limit Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Breztri Aerosphere – 10.7 grams/30 days • Cabenuva 400 mg/600 mg kit – 4 mL/28days • Cabenuva 600 mg/900 mg kit – 6 mL/28 days • Clindamycin gel – 120/30 days • Clindamycin solution – 120/30 days • Dulera 50 mcg – 13 grams/30 days • Gemtesa 75 mg tablet – 1/day • Lupkynis 7.9 mg capsule – 6/day • Orgovyx 120 mg tablet – 3/day • Ozempic 4 mg/3 mL – 3 mL/28 days • Rybelsus – 1/day • Tepmetko 225 mg tablet – 2/day • Trijardy XR 10-5-1000 mg tab – 1/day • Trijardy XR 12.5-2.5-1000 mg tab – 2/day • Trijardy XR 25-5-1000 mg tab – 1/day • Trijardy XR 5-2.5-1000 mg tab – 2/day • Ukoniq 200 mg tablet – 4/day • Vascepa 0.5 gm – 8/day • Vascepa 1 gm – 4/day • Vocabria 30 mg tablet – 1/day • Xeljanz solution – 10 mL/day 	<p>The Committee approved as presented. The Quantity Limit Additions will be sent to PARP for approval.</p>	<p>C. Casella</p>	<p>Resolved</p>

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<i>Specialty Drug Additions</i>	<p>The Committee reviewed the Specialty Drug Additions. The Committee approved as presented.</p> <ul style="list-style-type: none"> • Cabenuva • Evkeeza injection • Lupkynis • Orgovyx • Ukoniq 	The Committee approved as presented. The Specialty Drug Additions will be sent to PARP for approval.	C. Casella	Resolved
<i>New Drug Review</i>	<p>J. Daubert presented the New Drug Review list to the Committee. The following new products were reviewed and will be kept as non-formulary:</p> <ul style="list-style-type: none"> • Tepmetko (tepotinib) Tablets • Posimir (Bupivacaine) Solution for Infiltration Use • Lupkynis (voclosporin) • Vocabria (cabotegravir) • Verquvo (vericiguat) • Gemtesa (vibegron) Tablets • Ebanga (ansuvimab-zykl) Injection • Orgovyx (relugolix) Tablets • Riabni (rituximab-arrx) Injection • Margenza (margetuximab-cmkb) Injection • Klisyri (tirbanibulin) Ointment • Orladeyo (berotralstat) Capsules • Ga 68 PSMA-11 Injection • Danyelza (naxitamab-gqgk) Injection • Imcivree (setmelanotide) Injection • Oxlumo (lumasiran) Injection • Zokinvy (lonafarnib) Capsules • Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) Tablets • Sesquient (fosphenytoin sodium) for Injection • Bronchitol (mannitol) Inhalation Powder • Eysuvis (loteprednol etabonate) Ophthalmic Suspension • Veklury (remdesivir) Injection 	The Committee approved the New Drug Review as presented and recommended.	J. Daubert	Resolved

IV. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held May 2021.



3/24/2021

C. Casella, Director of Pharmacy Services
Pharmacy & Therapeutics Committee Meeting – 02-2021

Date